Novartis Reaches 1 Billion People Around the World

Our science-based innovations address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and search for new ways to reach as many people as possible.

Novartis is the second largest pharmaceutical company in the world in terms of global sales. In 2016, the company celebrated its 20th anniversary, while its predecessor companies  trace their roots back to 1758. Headquartered in Basel, Switzerland, Novartis develops innovative solutions that address the evolving needs of patients and societies. Its broad range of medicines covers key therapeutic areas: hematology, oncology, cardiology, immunology, dermatology, neurology, pulmonology, and ophthalmology.

Novartis research and development is driven by visionary thinking, scientific research, and new insights into individual diseases. More than 23 000 associates dedicate their work at Novartis exclusively to development. In the last five years, Novartis has been at the forefront in the pharmaceutical industry in terms of product approvals, and also obtained more than 10 approvals of breakthrough therapies from the US Food and Drug Administration (FDA).

Through various initiatives and cooperation (Novartis Access, Novartis Malaria Initiative, Novartis Healthy Family, SMS for Life, The Novartis Foundation), Novartis is actively involved in increasing access to medicines and healthcare.

The Novartis Commitment to Patients and Caregivers

The Commitment is the result of joint efforts of Novartis and over 40 patient organizations representing more than 200 million patients to further strengthen our efforts to find new ways to improve the lives of  all those who need our medicines. Find out more 

Our Business

We are structured to deliver innovative products, exploit global scale, and respond to new opportunities and risks. Our businesses – Innovative Medicines, Alcon and Sandoz – are supported by functional organizations with global scale. Research and development (R&D) is at the core of our company and central to the Novartis strategy.

Innovative Medicines

Made up of two business units – Pharmaceuticals and Oncology – our Innovative Medicines Division aims to bring more medicines to more patients more efficiently than any other drug development organization in the world. Find out more 

Alcon

Alcon provides innovative products that enhance quality of life by helping people worldwide see better. Find out more 

Sandoz

Sandoz is a global leader in generic pharmaceuticals and biosimilars that pioneers novel approaches to help people around the world access high-quality medicines. Find out more 

Novartis Institute for Biomedical Research (NIBR)

NIBR s the innovation engine of Novartis. We collaborate across scientific and organizational boundaries. Find out more 

Our Strategy

We believe Novartis is well prepared for a world with a growing, aging population and continuously evolving health needs. We have a clear mission, focused strategy and strong culture, all of which we expect will support the creation of value over the long term for our company, shareholders and society.

Novartis’ strategy is to use science based innovation to deliver better patient outcomes in growing areas of healthcare.

Science based innovations

We believe innovation that produces breakthrough medicines and products will be more important than ever in the healthcare industry in the coming years. Therefore, we maintain substantial investment in research and development (R&D) aimed at areas of unmet medical need. Our product pipeline is fed by a research and development approach that uses the latest science to advance the most promising projects.

Our research strategy aims to increase collaboration across traditional scientific and organizational boundaries, and focus on powerful new technologies that have the potential to help produce therapeutic breakthroughs. In drug development, we pursue promising therapies where we can leverage the scale and expertise of Novartis to bring important treatments to patients globally.

Better patient outcomes

We seek to develop medicines and products that can produce positive real-world outcomes for patients and healthcare providers. The benefits can range from improving the cost-effectiveness of high-quality care to prolonging lives.

We are developing services and technologies to augment the benefits of our core products, often in collaboration with healthcare providers and technology companies.

The disease areas we address are cancer, cardiovascular and metabolic diseases, immunology and dermatology, ophthalmology, neurology science and respiratory diseases.

Growing areas of healthcare

We aim to develop innovative products in growing areas of healthcare where we can make a real difference. We focus on patented medicines, generic medicines and eye care – segments where we have the innovation power and global scale necessary to compete effectively. At the same time, we are expanding our presence in the emerging markets of Asia, Africa and Latin America, where there is fast-growing demand for access to high-quality medicines and healthcare.